How Can Alembic Tap the US Generic Eye Drops Market?

Generic eye drops are emerging as an opportunity for Indian pharmaceutical manufacturers seeking to strengthen their presence in the US market.

Alembic Pharmaceuticals has received its final regulatory approval from the US FDA for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7 per cent (OTC), adding another product to its US generic drug portfolio.

The approval covers a formulation therapeutically equivalent to Alcon Laboratories' Pataday Once Daily Relief.

With the US market for this specific formulation estimated at USD 20 million, the development highlights the commercial potential of specialized ophthalmic products for Indian drug makers.

What does Alembic's olopatadine approval bring to the US market?

Alembic's latest USFDA clearance allows the company to market its generic version of olopatadine hydrochloride ophthalmic solution, 0.7 per cent, in the US.

The antihistamine eye drop is indicated for temporary relief from itchy eyes caused by pollen, ragweed, grass, animal hair and dander.

Key details of the approval include:

• Reference product: Pataday Once Daily Relief, 0.7 per cent, marketed by Alcon Laboratories.
• Market opportunity: USD 20 million in US sales for the 12 months ending September 2026.
• Development partner: Orbicular Pharmaceutical Technologies.
• Regulatory milestone: Alembic now has 248 cumulative ANDA approvals, comprising 229 final and 19 tentative approvals.

The clearance adds another specialized product to its US portfolio and strengthens its position in the generic eye drops segment.

Also Read: Strengthening India's Pharma Quality Infrastructure

How are Indian pharma companies competing in the US generic eye-drop market?

Dr. Reddy's Laboratories announced the first-to-market launch of its generic olopatadine 0.7 per cent ophthalmic solution in January 2026.

The company positioned the launch as an expansion of its over-the-counter eye-care portfolio, which already included olopatadine formulations in 0.1 per cent and 0.2 per cent strengths.

Milan Kalawadia, CEO of North America Generics at Dr. Reddy's Laboratories Inc., highlighted the company's capabilities in developing store-brand equivalents of OTC products and strengthening retail partnerships.

Why is ophthalmic drug manufacturing a specialized opportunity for India?

Ophthalmic formulations require specialized production and quality-control capabilities because products must meet stringent sterility and contamination-control requirements.

Important manufacturing considerations include:

• Sterile production: Maintaining controlled manufacturing environments to minimize microbial contamination.
• Quality assurance: Testing formulation consistency, stability and product quality.
• Packaging integrity: Ensuring suitable containers and closures protect the solution from contamination.
• Regulatory compliance: Meeting applicable USFDA requirements for manufacturing and product approval.

These requirements make generic eye drops a technically demanding segment, creating opportunities for Indian pharmaceutical companies with specialized formulation, sterile production and quality-assurance capabilities.

Alembic's collaboration with Orbicular also highlights the role of development partnerships in bringing ophthalmic products through the regulatory process.